Azathioprine with Allopurinol Is a Promising First-Line Therapy for Inflammatory Bowel Diseases

Area of Science:

• Immunology
• Gastroenterology
• Pharmacology

Background:

• First-line azathioprine (AZA) treatment for inflammatory bowel disease (IBD) has limited efficacy due to adverse events.
• Co-administration of allopurinol with AZA can enhance tolerability, but data on this combination as a first-line therapy are scarce.

Purpose of the Study:

• To compare the long-term effectiveness and safety of first-line low-dose azathioprine-allopurinol co-therapy (LDAA) versus azathioprine monotherapy (AZAm) in IBD patients.
• To evaluate clinical benefit, including ongoing therapy without escalation, and safety outcomes without metabolite monitoring.

Main Methods:

• Retrospective cohort study comparing LDAA and AZAm in IBD patients.
• Clinical benefit defined as maintaining therapy without steroids, biologics, or surgery.
• Secondary outcomes included C-reactive protein (CRP), Harvey-Bradshaw Index (HBI)/Simple Clinical Colitis Activity Index (SCCAI), steroid withdrawal, and adverse events.

Main Results:

• LDAA showed higher clinical benefit rates at 6 months (74% vs. 53%), 12 months (54% vs. 37%), and long-term (37% vs. 24%) compared to AZAm.
• AZAm patients were 60% more likely to discontinue therapy due to intolerance (45% vs. 26%).
• Myelotoxicity and elevated liver enzymes were similar between groups, with only 2% LDAA withdrawal for these reasons. Dose adjustment of allopurinol improved hepatotoxicity.

Conclusions:

• The suboptimal outcomes with AZAm highlight the need for treatment optimization.
• First-line LDAA demonstrates a safe and more effective long-term profile in IBD management.
• LDAA may be considered a standard first-line immunosuppressive option for IBD patients.